Glycogen Storage Disease 1A – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Glycogen Storage Disease 1A – Drugs In Development, 2024 report and make more profitable business decisions.
Glycogen storage disease type I (GSD I), also known as Von Gierke disease, is an inherited disorder caused by deficiencies of specific enzymes in the glycogen metabolism pathway. It comprises two major subtypes, GSD Ia and GSD Ib. In GSD Ia, there is a deficiency of enzyme glucose-6-phosphatase (G6Pase), which cleaves glycogen to glucose, thus leading to hypoglycemia and lactic acidosis.
The Glycogen Storage Disease 1A drugs in development market research report provide comprehensive information on the therapeutics under development for Glycogen Storage Disease 1A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glycogen Storage Disease 1A and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Glycogen Storage Disease 1A | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Glycogen Storage Disease 1A therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Glycogen Storage Disease 1A pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Glycogen Storage Disease 1A treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alexion Pharmaceuticals IncBeam Therapeutics Inc
Daiichi Sankyo Co Ltd
Liberyx Therapeutics Ltd
Moderna Inc
Soleno Therapeutics Inc
Ultragenyx Pharmaceutical Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Glycogen Storage Disease 1A reports